ESMO Breast 2024 | Addressing suboptimal ovarian suppression in PREFER and GIM 23 studies

Simone Nardin • 17 May 2024

ESMO Breast 2024

Breast Cancer

Simone Nardin, MD, Ospedale Policinico San Martino, Genoa, Italy, discusses the analysis of suboptimal ovarian suppression during adjuvant endocrine therapy in the PREFER (NCT02895165) and GIM 23 (NCT05730647) studies. These studies focus on patients with premenopausal HR-positive breast cancer undergoing endocrine therapy. The analysis aims to understand the prevalence of suboptimal ovarian suppression and explore treatment options to improve outcomes. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.